Fosamprenavir
- Generic Name
- Fosamprenavir
- Brand Names
- Lexiva, Telzir
- Drug Type
- Small Molecule
- Chemical Formula
- C25H36N3O9PS
- CAS Number
- 226700-79-4
- Unique Ingredient Identifier
- WOU1621EEG
- Background
Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.
- Indication
Indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. The use of fosamprenavir is pending revision due to a potential association between the drug and myocardial infarction and dyslipidemia in HIV infected adults.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects
- Conditions
- HIV InfectionInfection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2010-11-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 211
- Registration Number
- NCT00363142
- Locations
- 🇵🇷
GSK Investigational Site, San Juan, Puerto Rico
A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects
- Conditions
- Infection, Human Immunodeficiency Virus
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2013-04-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 753
- Registration Number
- NCT00296504
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
"The Once A Day Protease Inhibitor Regimens"
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2014-01-15
- Target Recruit Count
- 76
- Registration Number
- NCT00242216
- Locations
- 🇺🇸
Thomas Street Health Center, Houston, Texas, United States
Fosamprenavir Expanded Access
- Conditions
- Infection, Human Immunodeficiency Virus
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2016-09-12
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 85
- Registration Number
- NCT00240552
- Locations
- 🇨🇭
GSK Investigational Site, Zurich, Switzerland
Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2011-12-22
- Lead Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
- Target Recruit Count
- 61
- Registration Number
- NCT00122603
- Locations
- 🇫🇷
Service des Maladies infectieuses et tropicales Hopital Bichat Claude Bernard, Paris, France
Fosamprenavir Versus Other Protease Inhibitors
- First Posted Date
- 2004-10-21
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 314
- Registration Number
- NCT00094523
- Locations
- 🇵🇷
GSK Investigational Site, Ponce, Puerto Rico
48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection
- Conditions
- Infection, Human Immunodeficiency Virus I
- Interventions
- First Posted Date
- 2004-08-10
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 110
- Registration Number
- NCT00089583
- Locations
- 🇪🇸
GSK Investigational Site, Vigo ( Pontevedra), Spain
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
- Conditions
- HIV InfectionInfection, Human Immunodeficiency Virus
- First Posted Date
- 2004-06-21
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 866
- Registration Number
- NCT00085943
- Locations
- 🇨🇭
GSK Investigational Site, St Gallen, Switzerland
Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
- Conditions
- Infection, Human Immunodeficiency VirusHIV Infections
- Interventions
- First Posted Date
- 2003-10-31
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 59
- Registration Number
- NCT00071760
- Locations
- 🇿🇦
GSK Investigational Site, Soweto, South Africa
Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR
- Conditions
- HIV Infections
- First Posted Date
- 2002-08-19
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00043888
- Locations
- 🇬🇧
GSK Clinical Trials Call Center, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.